VYJUVEK 5x10^9 UFP / ml suspension and gel for gel medication leaflet

D03AX16 • beremagene geperpavec • Dermatologicals | Cicatrizants | Other cicatrizants

Beremagene geperpavec is a gene therapy applied to the skin to treat wounds in people with dystrophic epidermolysis bullosa caused by changes in the COL7A1 gene. This rare inherited condition makes the skin very fragile, leading to blisters, painful wounds and scarring. The medicine is not a cure, but it can help treated wounds close and heal more reliably.

The treatment contains a modified herpes simplex type 1 virus that cannot multiply or cause herpes disease. Its purpose is to deliver a working copy of the COL7A1 gene into skin cells. These cells can then make type VII collagen, a protein that helps hold the layers of the skin together and reduces the tendency of wounds to reopen.

Beremagene geperpavec is supplied as a gel and is applied directly to wounds, usually once weekly. Treatment should be started by a healthcare team experienced in dystrophic epidermolysis bullosa. In some cases, a trained patient or caregiver may apply it. It should not be used on skin without wounds, and the weekly dose limit and dressing instructions must be followed carefully.

Possible side effects include itching, chills, redness or discomfort at the application site. After treatment, avoid touching treated wounds and dressings until the advised dressing change. Contact your doctor if you notice fever, worsening wounds, signs of infection, allergic symptoms, or if the treatment no longer seems to control the wound problems.